New trial
Phase 2 Study of Blinatumomab (CD19 Targeted) and Venetoclax (BCL2 Inhibitor) in KMT2A-Altered Infant ALL
- Trial ID
- NCT06317662 on ClinicalTrials.gov
- Cancer type
- Hematological Cancer
- Location
- 3 Locations
- Published in
- New in Oncology - May 29, 2025
This trial evaluates the safety and efficacy of adding CD19-directed blinatumomab and BCL2 inhibitor venetoclax to standard chemotherapy in infants with newly diagnosed ALL with either KMT2A rearrangement or germline, aiming to improve outcomes in this high‐risk population.
More in other blood cancers and transplant
-
Trial result · Aug 13, 2026 · NCT04904588
Standard-dose PTCy enables mismatched-donor HCT but carries substantial early infection burden -
Trial result · Aug 6, 2026 · NCT05388123
Low-dose vemurafenib (BRAF V600E inhibitor) + rituximab drives 73% CR with zero grade 3-4 AEs in HCL -
Trial result · Aug 6, 2026 · NCT02113982
Tagraxofusp (CD123-directed cytotoxin) in BPDCN delivers 71%–90% ORR across trials—HSCT bridge drives survival -
New trial · Jun 25, 2026 · NCT07634536
Phase 2 automated VMAT-based TMLI conditioning refines marrow / lymphoid-targeted irradiation for allo-HCT. -
New trial · Jun 25, 2026 · NCT07572006
Phase 1 JNJ-95804306 (no disclosed MOA/target) in relapsed/refractory AML/MDS and CLL/SLL